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Modified Temporary Cardiac Pacing Using Transvenous Active Fixation Leads and
External Re-Sterilized Pulse Generators
To the Editor: Transcutaneous temporary pacing can be unreli-
able, and the stimulation can be uncomfortable; epicardial pacing
requires thoracotomy (1,2). Transvenous percutaneous pacing
systems placed “blindly,” fluoroscopically, or electrocardiographi-
cally have therefore become the mainstay of temporary pacing (1).
However, temporary pacing leads have a significant risk of dis-
lodgement, infection, loss of capture, or even chamber perforation
(3). In addition to risk of infection with prolonged central venous
access, patient immobilization (“bed rest”) can result in additional
complications and economic burden.
As a result, use of temporary pacing systems is limited to no
more than a few days (1). However, prolonged temporary pacing
may sometimes be required. Treatment of infection in a
pacemaker-dependent patient (4), post-operative recovery from
cardiac valve surgery (5), or Lyme myocarditis with transient
atrioventricular (AV) block (6) are representative of cases where
prolonged pacing support may be necessary.
We present an alternative approach for modified temporary
pacing support to address these scenarios. An active fixation pacing
lead is placed fluoroscopically via percutaneous venous access and
connected to a re-sterilized external pulse generator. This paper
describes our clinical experience with this pacing system.
All patients who received modified temporary pacing support by
the arrhythmia service at Brigham and Women’s Hospital from
July 2000 through November 2004 were included in the analysis.
The facility is a regional referral center for lead extraction, resulting
in a significant number of patients admitted with infected devices.
Patient clinical characteristics, details of the implantation proce-
dure, and follow-up results were evaluated.
If the commonly accepted indication for pacing (7) was potentially
reversible but likely to persist for more than one or two days, or if
the patient had a treatable contraindication to permanent hardware
implantation, a modified temporary pacing system was considered.
New standard active-fixation leads were selected at physician
discretion. Pulse generators previously explanted from patients
without known infection were re-sterilized and utilized. In a sterile
procedure room, venous access was achieved using standard per-
cutaneous technique (without cutdown) (Fig. 1). The pacing lead
was advanced under fluoroscopic guidance, fixed to the myocar-
dium, and tested in a standard fashion. The lead was then sutured
to the skin using the anchoring sleeve (Fig. 1). After connection to
the lead, the pulse generator (programmed SSI) was secured to the
skin surface (Fig. 2).
After implantation, patients were returned to their hospital beds
and, unless contraindicated, were encouraged to ambulate. Plain
film chest radiography and interrogation were performed the
following day to exclude acute dislodgment. Patients were followed
clinically to determine if a permanent device was still indicated
and/or if concurrent infection or illness had resolved sufficiently to
allow permanent device implantation. At the time of permanent
implantation, the external pulse generator was detached followed
by retraction of the active fixation mechanism from the myocar-
dium under fluoroscopic guidance.
Figure 1. Implant technique schematic. (A) The pacing lead is inserted via
percutaneous access and placed in the right ventricle (or atrium). (B) An
extendable-retractable active fixation lead is used to reduce migration. (C)
The proximal lead remains external to the patient, is anchored via suture
sleeve to the skin, and attached to the external pulse generator.
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The 62 patients receiving modified temporary pacing were
68.4  14.2 years of age (n  37, 59.7% male), with a mean left
ventricular ejection fraction of 47  2%. Twenty-six patients
(41%) had known coronary artery disease. The median hospital
length of stay was 18 days. Indications for pacing were symptom-
atic AV block (n  39, 62.9%), sick sinus syndrome (n  17,
27.4%), and one instance of drug-related torsades de pointes.
Reasons for delaying permanent device implantation included
bacteremia (n  27, 43.5%), early post-cardiac surgery (n  17,
27.4%), concurrent medical illness (n  6, 9.7%), serologically
confirmed Lyme disease (n  3, 4.8%), and miscellaneous (n  9,
14.5%). Among patients with bacteremia, most were elective
admissions for lead and generator extraction for infection (n  10,
37.0%) or primary diagnoses of endocarditis (n  3, 11.1%).
Central venous access was via the internal jugular (n  31,
47.7%), axillary (n  21, 32.3%), subclavian (n  11, 16.9%),
cephalic (requiring cutdown, n  1, 1.5%), and femoral (requiring
bed rest, n  1, 1.5%) veins. The majority of leads were placed in
the right ventricular apex (n  59, 95.2%), although three patients
received right atrial pacing support.
The median duration of modified temporary pacemaker im-
plantation was 7.5 days. Approximately two-thirds (n  41,
66.1%) received permanent device implantation during index
hospitalization. Of the 21 patients not felt to be candidates for
permanent pacemaker implantation, 9 (42.9%) no longer required
pacing support. All Lyme myocarditis patients recovered AV
conduction, and none required permanent pacing, with time to
recovery between 6 to 11 days. Among the post-operative patients,
two died from non-arrhythmic causes during hospitalization, and
five (23.8%) recovered conduction, obviating the need for perma-
nent pacing. Among the remaining patients, nine (42.9%) died of
non-arrhythmic causes during hospitalization, and three were
transferred to the referring hospital for further treatment, primarily
for infection, followed by permanent device implantation there.
No deaths were due to arrhythmia. No implant-related com-
plications were observed, including lead dislodgment, perforation,
pericardial effusion, or device infection. In those patients initially
in an intensive care setting due to pacing support requirement,
providers were encouraged to transfer the patient to a “step-down”
or telemetry ward.
In the largest case series to date, we demonstrate an alternative
approach to provide intermediate-term pacing (8). The advantages
include lead position stability, allowance for full treatment of
infections before permanent device placement, and an extended
period of observation for recovery of normal conduction. Patients
with significant risk of mortality are allowed to follow a natural
history without the expense of permanent hardware implantation.
These re-sterilized pulse generators are free of known infection
and only contact the patient’s skin, resulting in minimal additional
infection risk.
This series represents patients that are generally high risk,
referrals, and have a high incidence of device infection. Patients
with acute myocardial infarction requiring temporary pacing are
generally treated in our cardiac catheterization laboratory; this
important subset of patients is not addressed. These points may
limit the generalizability of our findings. Other approaches to
intermediate duration pacing have been described utilizing special-
ized pacing wires with active fixation mechanisms (9). Compari-
sons to these other temporary pacing systems should not be
inferred and are beyond the scope of this analysis.
This pacing system requires no new technology and utilizes
equipment already available to the implanting physician. It pro-
vides safe, stable, and reliable pacing in the individual who is
immediately pacemaker-dependent but has reasons for delay in
Figure 2. A newly implanted modified temporary pacing system is shown, with central venous access via axillary vein puncture. The proximal lead is external
and sutured to the skin. A pulse generator is attached and then taped to the skin.
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permanent device implantation. We believe this system can be
readily implemented in such clinical scenarios.
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Brain Natriuretic Peptide Levels in Constrictive Pericarditis and Restrictive Cardiomyopathy
To the Editor: Constrictive pericarditis (CP) often is a challeng-
ing diagnosis despite sophisticated modalities (1–4). If a simple
test could alert physicians to the possibility of CP in patients with
evidence of heart failure, it would be valuable.
Recent data (5) suggest that brain natriuretic peptide (BNP),
released in response to cardiac stretch (6), is normal or only
minimally elevated in patients with CP and more elevated in
patients with restrictive cardiomyopathy (RCMP). However, there
are a variety of etiologies for CP. Many patients at our institution
present after either mantle chest radiation and/or open heart
surgical procedures (7). These patients may have additional myo-
cardial damage that could raise BNP even when concomitant CP
is present. To determine whether BNP levels in all patients with
CP are different from those with restriction, we studied patients
with well-documented CP and RCMP. We separated patients
with CP into those with idiopathic disease and with CP due to
secondary causes.
We reviewed 22 patients with surgically confirmed CP where
BNP was measured pre-operatively. Patients were divided into
those with idiopathic CP or secondary CP if there had been
previous cardiac surgery or chest radiation. We identified patients
with RCMP who had appropriately timed BNP values as a
comparison group. The diagnosis of RCMP was made according
to criteria by Hurrell et al. (4). These patients also had character-
istic echocardiographic findings. The diagnosis of CP was con-
firmed at surgery.
Two-dimensional echocardiographic examinations were per-
formed as previous reported (8); BNP measurements were per-
formed with the Biosite assay (La Jolla, California) close to the
time of the echocardiographic examinations and before surgical
pericardiectomy. The interval between echocardiogram and BNP
measurement was 1.3  7.4 days, and in all patients except 6, the
interval was 1 day.
Summary statistics are presented as frequencies (percentages)
for categorical variables, as mean  SD for the normal variables,
and as median and first and third quartile (Q1, Q3) for skewed
variables. The normal distribution of the variables was verified
performing the Shapiro-Wilk W test. Only BNP was very right
skewed. Log10-transformed values of BNP (Log10BNP) were
used in the analysis to obtain a normal distribution of the values.
Categorical variables were compared by Fisher exact test, contin-
uous normal variables by analysis of variance (followed by Tukey’s
HDS post-test). All tests were two-sided, and for all analyses p 
0.05 was considered statistically significant. Data were analyzed
with JMP Version 5 (SAS Institute Inc., Cary, North Carolina).
Twenty-two patients had surgically confirmed CP, 11 patients
had idiopathic CP, and 11 secondary CP (8 with previous cardiac
surgery and 3 with radiation therapy). They were compared to 11
patients with RCMP. Patient characteristics are reported in Table 1.
There were no significant differences among groups. Median BNP
was 80 (44 to 193) ng/l for idiopathic CP, 278 (118 to 526) ng/l
for secondary CP, and 499 (361 to 606) ng/l for RCMP. The
Log10-BNP was 1.9  0.3 ng/l for idiopathic CP, 2.4  0.3 ng/l
for secondary CP, and 2.7  0.2 ng/l for RCMP. There was a
statistically significant difference between the BNP values with
idiopathic CP and RCMP (p  0.05) and between patients with
idiopathic CP and those with secondary CP (p  0.05). There
were no significant differences in BNP between patients with
secondary CP and RCMP (Fig. 1).
All patients with BNP 150 ng/l had CP. Higher BNPs were
seen in patients with secondary CP and RCMP. The only
differentiating finding with RCMP was a BNP 650 ng/l, which
did not occur with CP.
Our data confirm and extend those recently published (5). Brain
natriuretic peptide levels were significantly lower in patients with
idiopathic CP than those with RCMP. However, BNP is not
significantly different in patients with CP secondary to previous
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